Coya Therapeutics to progress trial of ALS treatment upon FDA approval
Written by
PharmaTimes
Published
0
comments
0
min
The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application from Coya Therapeutics for COYA 302, enabling the company to begin a phase 2 clinical trial in patients with amyotrophic lateral sclerosis (ALS). The study will assess the safety and efficacy of COYA 302, a biologic therapy designed to regulate […]